MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 31, 2007; DOI: 10.1124/mol.106.027763


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.027763v1
71/5/1222    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bolan, E. A.
Right arrow Articles by Shippenberg, T. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bolan, E. A.
Right arrow Articles by Shippenberg, T. S.


Received for publication June 9, 2006.
Revised January 30, 2007.
Accepted for publication January 31, 2007.

D2 Receptors Regulate Dopamine Transporter Function Via an ERK 1/2-Dependent and PI3 Kinase-Independent Mechanism

Elizabeth A. Bolan 1, Bronwyn Kivell 1, Vanaja Jaligam 1, Murat Oz 1, Lankupalle D Jayanthi 2, Yang Han 3, Namita Sen 3, Eneki Urizar 3, Ivone Gomes 4, Lakshmi A Devi 4, Sammanda Ramamoorthy 2, Jonathan A Javitch 3, Agustin Zapata 1, Toni S. Shippenberg 1*

1 NIH-NIDA 2 MUSC 3 Columbia University 4 Mount Sinai School of Medicine

* Address correspondence to: E-mail: tshippen{at}intra.nida.nih.gov

Abstract

ABSTRACT The dopamine transporter (DAT) terminates dopamine (DA) neurotransmission by reuptake of DA into presynaptic neurons. Regulation of DA uptake by D2 dopamine receptors (D2R) has been reported. The high affinity of DA and other DAT substrates for the D2R, however, has complicated investigation of the intracellular mechanisms mediating this effect. The present studies used the fluorescent DAT substrate, 4-[4-(diethylamino)-styryl]-N-methylpyridinium iodide (ASP+) with live cell imaging techniques to identify the role of two D2R-linked signaling pathways, extracellular signal-regulated kinases 1 and 2 (ERK 1/2) and phosphoinositide 3 kinase (PI3K), in mediating D2R regulation of DAT. Addition of the D2/D3 receptor agonist quinpirole (0.1-10 µM) to human embryonic kidney cells co-expressing human DAT and D2 receptor (short splice variant, D2SR) induced a rapid, concentration-dependent and pertussis toxin-sensitive increase in ASP+ accumulation. The D2/D3 agonist, PD128907 also increased ASP+ accumulation. D2SR activation increased phosphorylation of ERK 1/2 and Akt, a major target of PI3K. The MEK inhibitor, PD98059, prevented the quinpirole-evoked increase in ASP+ accumulation, whereas inhibition of PI3K was without effect. Fluorescence flow cytometry and biotinylation studies revealed a rapid increase in DAT cell-surface expression in response to D2R stimulation. These experiments demonstrate that D2SR stimulation increases DAT cell surface expression and therefore enhances substrate clearance. Furthermore, they show that the increase in DAT function is ERK 1/2-dependent but PI3K-independent. Our data also suggest the possibility of a direct physical interaction between DAT and D2R. Together, these results suggest a novel mechanism by which D2SR autoreceptors may regulate DAT in the CNS.


Key words: Dopamine, MAP Kinase, Biogenic Amine, Fluorescence techniques


This article has been cited by other articles:


Home page
Mol. Biol. CellHome page
O. V. Mortensen, M. B. Larsen, B. M. Prasad, and S. G. Amara
Genetic Complementation Screen Identifies a Mitogen-activated Protein Kinase Phosphatase, MKP3, as a Regulator of Dopamine Transporter Trafficking
Mol. Biol. Cell, July 1, 2008; 19(7): 2818 - 2829.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Z. Xie and G. M. Miller
{beta}-Phenylethylamine Alters Monoamine Transporter Function via Trace Amine-Associated Receptor 1: Implication for Modulatory Roles of Trace Amines in Brain
J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 617 - 628.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. J. Samuvel, L. D. Jayanthi, S. Manohar, K. Kaliyaperumal, R. E. See, and S. Ramamoorthy
Dysregulation of Dopamine Transporter Trafficking and Function after Abstinence from Cocaine Self-Administration in Rats: Evidence for Differential Regulation in Caudate Putamen and Nucleus Accumbens
J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 293 - 301.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Zapata, B. Kivell, Y. Han, J. A. Javitch, E. A. Bolan, D. Kuraguntla, V. Jaligam, M. Oz, L. D. Jayanthi, D. J. Samuvel, et al.
Regulation of Dopamine Transporter Function and Cell Surface Expression by D3 Dopamine Receptors
J. Biol. Chem., December 7, 2007; 282(49): 35842 - 35854.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. Marazziti, S. Mandillo, C. Di Pietro, E. Golini, R. Matteoni, and G. P. Tocchini-Valentini
GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs
PNAS, June 5, 2007; 104(23): 9846 - 9851.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics